Company news

Unicycive Therapeutics, Inc. news in 2026

Unicycive Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update

November 16, 2026

Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference

November 4, 2026

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027

October 21, 2026

Unicycive Therapeutics Appoints Meredith Manning to Board of Directors

October 1, 2026

Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate

September 29, 2026

Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 1, 2026

Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

August 12, 2026

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

April 8, 2026

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

March 29, 2026

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit

February 4, 2026

UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

January 29, 2026

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

January 29, 2026

Decks in 2026